Nature Communications (Aug 2024)
A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine
- Pauline Latzer,
- Henning Zelba,
- Florian Battke,
- Annekathrin Reinhardt,
- Borong Shao,
- Oliver Bartsch,
- Armin Rabsteyn,
- Johannes Harter,
- Martin Schulze,
- Thomas Okech,
- Alexander Golf,
- Christina Kyzirakos-Feger,
- Simone Kayser,
- Natalia Pieper,
- Magdalena Feldhahn,
- Julian Wünsche,
- Christian Seitz,
- Dirk Hadaschik,
- Claus Garbe,
- Till-Karsten Hauser,
- Christian la Fougère,
- Dirk Biskup,
- Dawn Brooke,
- David Parker,
- Uwe M. Martens,
- Gerald Illerhaus,
- Deborah T. Blumenthal,
- Ryan Merrell,
- Luisa Sánchez Lorenzo,
- Máté Hidvégi,
- Paula de Robles,
- Sied Kebir,
- William W. Li,
- Vincent W. Li,
- Matthew Williams,
- Alexandra M. Miller,
- Santosh Kesari,
- Michael Castro,
- Annick Desjardins,
- David M. Ashley,
- Henry S. Friedman,
- Patrick Y. Wen,
- Elisabeth C. Neil,
- Fabio M. Iwamoto,
- Bence Sipos,
- Karsten Geletneky,
- Lars Zender,
- Martin Glas,
- David A. Reardon,
- Saskia Biskup
Affiliations
- Pauline Latzer
- Zentrum für Humangenetik Tübingen
- Henning Zelba
- Zentrum für Humangenetik Tübingen
- Florian Battke
- CeGaT GmbH
- Annekathrin Reinhardt
- Zentrum für Humangenetik Tübingen
- Borong Shao
- Zentrum für Humangenetik Tübingen
- Oliver Bartsch
- Zentrum für Humangenetik Tübingen
- Armin Rabsteyn
- Zentrum für Humangenetik Tübingen
- Johannes Harter
- CeGaT GmbH
- Martin Schulze
- Zentrum für Humangenetik Tübingen
- Thomas Okech
- MVZ Zentrum für ambulante Onkologie GmbH
- Alexander Golf
- MVZ Zentrum für ambulante Onkologie GmbH
- Christina Kyzirakos-Feger
- Zentrum für Humangenetik Tübingen
- Simone Kayser
- Zentrum für Humangenetik Tübingen
- Natalia Pieper
- Zentrum für Humangenetik Tübingen
- Magdalena Feldhahn
- CeGaT GmbH
- Julian Wünsche
- Zentrum für Humangenetik Tübingen
- Christian Seitz
- Universitätsklinikum Heidelberg, KiTZ, Hopp Children’s Cancer Center
- Dirk Hadaschik
- CeCaVa GmbH
- Claus Garbe
- Department of Dermatology, University Hospital Tübingen
- Till-Karsten Hauser
- Department für Radiologie, Universitätsklinikum Tübingen
- Christian la Fougère
- Nuklearmedizin und Klinische Molekulare Bildgebung, Universitätsklinikum Tübingen
- Dirk Biskup
- CeGaT GmbH
- Dawn Brooke
- Provenance Precision Medicine Foundation
- David Parker
- PHM
- Uwe M. Martens
- Department of Hematology and Oncology, Cancer Center Heilbronn-Franken, SLK Kliniken GmbH
- Gerald Illerhaus
- Klinikum Stuttgart
- Deborah T. Blumenthal
- Tel-Aviv Sourasky Medical Center, Tel-Aviv University
- Ryan Merrell
- Vanderbilt University Medical Center
- Luisa Sánchez Lorenzo
- Clínica Universidad de Navarra
- Máté Hidvégi
- Jewish Theological Seminary—University of Jewish Studies (OR-ZSE)
- Paula de Robles
- Department of Clinical Neurosciences, University of Calgary
- Sied Kebir
- Universitätsklinikum Essen
- William W. Li
- Angiogenesis Foundation
- Vincent W. Li
- Angiogenesis Foundation
- Matthew Williams
- NHS London
- Alexandra M. Miller
- Brain and Spine Tumor Center, NYU Langone Health’s Perlmutter Cancer Center
- Santosh Kesari
- Pacific Neuroscience Institute, Saint John’s Cancer Institute, Providence Saint John’s Health Center
- Michael Castro
- Cellworks Group Inc
- Annick Desjardins
- Department of Neurosurgery, Duke University Medical Center
- David M. Ashley
- Department of Neurosurgery, Duke University Medical Center
- Henry S. Friedman
- Department of Neurosurgery, Duke University Medical Center
- Patrick Y. Wen
- Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Elisabeth C. Neil
- Department of Neurology, University of Minnesota Health
- Fabio M. Iwamoto
- Columbia University Medical Center
- Bence Sipos
- BAG für Pathologie und Molekularpathologie Stuttgart, Molekularpathologie Baden-Württemberg GbR
- Karsten Geletneky
- Klinikum Darmstadt GmbH
- Lars Zender
- University Hospital Tübingen, Internal Medicine VIII
- Martin Glas
- Division of Clinical Neurooncology, Department of Neurology, Universitätsklinikum Essen Klinik für Neurologie
- David A. Reardon
- Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Saskia Biskup
- Zentrum für Humangenetik Tübingen
- DOI
- https://doi.org/10.1038/s41467-024-51315-8
- Journal volume & issue
-
Vol. 15,
no. 1
pp. 1 – 9
Abstract
Abstract Current treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to generate a personalized peptide vaccine targeting tumor-specific neoantigens. All patients were treated within the scope of an individual healing attempt. Among all vaccinated patients, including 70 treated prior to progression (primary) and 103 treated after progression (recurrent), the median overall survival from first diagnosis is 31.9 months (95% CI: 25.0–36.5). Adverse events are infrequent and are predominantly grade 1 or 2. A vaccine-induced immune response to at least one of the vaccinated peptides is detected in blood samples of 87 of 97 (90%) monitored patients. Vaccine-specific T-cell responses are durable in most patients. Significantly prolonged survival is observed for patients with multiple vaccine-induced T-cell responses (53 months) compared to those with no/low induced responses (27 months; P = 0.03). Altogether, our results highlight that the application of personalized neoantigen-targeting peptide vaccine is feasible and represents a promising potential treatment option for GBM patients.
